Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Hypokalaemia associated with hydrochlorothiazide used in the treatment of hypertension in NHANES 1999–2018

Abstract

Hydrochlorothiazide is the most common thiazide diuretic used for hypertension in the US. Yet, hypokalaemia is a well-recognised adverse effect. To evaluate the prevalence and factors associated with hypokalaemia (serum potassium < 3.5 mmol/L) among hydrochlorothiazide users, we included US adults aged ≥20 years in the 1999–2018 National Health and Nutrition Examination Survey. Participants were categorised according to the use of hydrochlorothiazide and other antihypertensive agents. Factors associated with hypokalaemia, including demographics and prescription patterns (monotherapy vs single-pill fixed-dose combination vs polytherapy) were studied using multivariable logistic regression. Hypokalaemia was present in 12.6% of the hydrochlorothiazide users, equivalent to ~2.0 million US adults. Women (adjusted OR, 2.22; 95% CI, 1.74–2.83), non-Hispanic blacks (adjusted OR, 1.65; 95% CI, 1.31–2.08), underweight (adjusted OR, 4.33; 95% CI, 1.34–13.95), and participants taking hydrochlorothiazide for five years or more (adjusted OR, 1.47; 95% CI, 1.06–2.04) had a higher risk of hypokalaemia. Compared to monotherapy, fixed-dose combination therapy (adjusted OR, 0.32; 95% CI, 0.21–0.48) was associated with the lowest risk. Among those taking potassium supplements, hypokalaemia was found in 27.2% of participants on monotherapy and 17.9% on polytherapy. The prevalence of hypokalaemia among hydrochlorothiazide users was considerable, even among participants who also took potassium supplements. Women, ethnic minorities, underweight, monotherapy, and participants with long-term therapy are more likely to have hypokalaemia. Regular monitoring of potassium and combination with potassium-sparing drugs are needed.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1
Fig. 2

Data availability

Data used in this study are available from the published data of the NHANES database (https://www.cdc.gov/nchs/nhanes/index.htm).

References

  1. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.

    Article  Google Scholar 

  2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72.

    CAS  Article  Google Scholar 

  3. Michael E, Ernst MM. Use of diuretics in patients with hypertension. N Engl J Med. 2009;361:2153–64.

    Article  Google Scholar 

  4. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension. 2000;35:1025–30.

    CAS  Article  Google Scholar 

  5. Schnaper HW, Freis ED, Friedman RG, Garland WT, Hall WD, Hollifield J, et al. Potassium restoration in hypertensive patients made hypokalemic by hydrochlorothiazide. Arch Intern Med. 1989;149:2677–81.

    CAS  Article  Google Scholar 

  6. Alfonzo AV, Isles C, Geddes C, Deighan C. Potassium disorders-clinical spectrum and emergency management. Resuscitation. 2006;70:10–25.

    Article  Google Scholar 

  7. Kardalas E, Paschou SA, Anagnostis P, Muscogiuri G, Siasos G, Vryonidou A. Hypokalemia: a clinical update. Endocr Connect. 2018;7:R135–r146.

    CAS  Article  Google Scholar 

  8. Roush GC, Ernst ME, Kostis JB, Kaur R, Sica DA. Not just chlorthalidone: evidence-based, single tablet, diuretic alternatives to hydrochlorothiazide for hypertension. Curr Hypertens Rep. 2015;17:540.

    Article  Google Scholar 

  9. The ClinCalc DrugStats Database. (2021). Hydrochlorothiazide, drug usage statistics, United States, 2013–2019. https://clincalc.com/DrugStats/Drugs/Hydrochlorothiazide. Accessed Sep 2021.

  10. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75:1334–57.

    CAS  Article  Google Scholar 

  11. Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394:1816–26.

    Article  Google Scholar 

  12. de Cates AN, Farr MR, Wright N, Jarvis MC, Rees K, Ebrahim S, et al. Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev. 2014;4:CD009868.

    Google Scholar 

  13. Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension. 2015;65:1041–6.

    CAS  Article  Google Scholar 

  14. National Center for Health Statistics, Centers for Disease Control and Prevention. (2020). NHANES response rates and population totals. https://wwwn.cdc.gov/nchs/nhanes/ResponseRates.aspx#response-rates. Accessed Aug 2021.

  15. National Center for Health Statistics, Centers for Disease Control and Prevention. (2020). NHANES questionnaires, datasets, and related documentation. https://wwwn.cdc.gov/nchs/nhanes/default.aspx. Accessed Aug 2021.

  16. Krogager ML, Kragholm K, Thomassen JQ, Søgaard P, Lewis BS, Wassmann S, et al. Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J Cardiovasc Pharmacother. 2021;7:557–67.

    Article  Google Scholar 

  17. Palmer BF, Carrero JJ, Clegg DJ, Colbert GB, Emmett M, Fishbane S, et al. Clinical management of hyperkalemia. Mayo Clin Proc. 2021;96:744–62.

    CAS  Article  Google Scholar 

  18. National Health and Nutrition Examination Survey. (2020). 2017-2018 data documentation, codebook, and frequencies. https://wwwn.cdc.gov/Nchs/Nhanes/2017-8/BIOPRO_J.htm#Analytic_Notes. Accessed Aug 2021.

  19. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.

    Article  Google Scholar 

  20. Gennari FJ. Hypokalemia. N Engl J Med. 1998;339:451–8.

  21. Nilsson E, Gasparini A, Ärnlöv J, Xu H, Henriksson KM, Coresh J, et al. Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system. Int J Cardiol. 2017;245:277–84.

    Article  Google Scholar 

  22. Thoenes M, Neuberger HR, Volpe M, Khan BV, Kirch W, Böhm M. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens. 2010;24:336–44.

    CAS  Article  Google Scholar 

  23. Rydberg DM, Mejyr S, Loikas D, Schenck-Gustafsson K, von Euler M, Malmström RE. Sex differences in spontaneous reports on adverse drug events for common antihypertensive drugs. Eur J Clin Pharm. 2018;74:1165–73.

    CAS  Article  Google Scholar 

  24. Sun H, Weaver CM. Rising trend of hypokalemia prevalence in the US population and possible food causes. J Am Coll Nutr. 2021;40:273–9.

    CAS  Article  Google Scholar 

  25. Chen Y, Sang Y, Ballew SH, Tin A, Chang AR, Matsushita K, et al. Race, serum potassium, and associations with ESRD and mortality. Am J Kidney Dis. 2017;70:244–51.

    CAS  Article  Google Scholar 

  26. Kovesdy CP, Appel LJ, Grams ME, Gutekunst L, McCullough PA, Palmer BF, et al. Potassium homeostasis in health and disease: a scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension. J Am Soc Hypertens. 2017;11:783–800.

    CAS  Article  Google Scholar 

  27. Mariosa LSS, Ribeiro‐Filho FF, Batista MC, Hirota AH, Borges RL, Ribeiro AB, et al. Abdominal obesity is associated with potassium depletion and changes in glucose homeostasis during diuretic therapy. J Clin Hypertens. 2008;10:443–9.

    CAS  Article  Google Scholar 

  28. Palmer BF. Regulation of potassium homeostasis. Clin J Am Soc Nephrol. 2015;10:1050–60.

    CAS  Article  Google Scholar 

  29. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399–407.

    CAS  Article  Google Scholar 

  30. Clayton JA, Rodgers S, Blakey J, Avery A, Hall IP. Thiazide diuretic prescription and electrolyte abnormalities in primary care. Br J Clin Pharm. 2006;61:87–95.

    CAS  Article  Google Scholar 

  31. Chang AR, Sang Y, Leddy J, Yahya T, Kirchner HL, Inker LA, et al. Antihypertensive medications and the prevalence of hyperkalemia in a large health system. Hypertension. 2016;67:1181–8.

    CAS  Article  Google Scholar 

  32. Krogager ML, Torp-Pedersen C, Mortensen RN, Kober L, Gislason G, Sogaard P, et al. Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data. Eur Heart J. 2017;38:104–12.

    CAS  PubMed  Google Scholar 

  33. Cohn JN, Kowey PR, Whelton PK, Prisant LM. New guidelines for potassium replacement in clinical practice: a contemporary review by the National Council on Potassium in Clinical Practice. Arch Intern Med. 2000;160:2429–36.

    CAS  Article  Google Scholar 

  34. Kaplan NM, Carnegie A, Raskin P, Heller JA, Simmons M. Potassium supplementation in hypertensive patients with diuretic-induced hypokalemia. N Engl J Med. 1985;312:746–9.

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

ZL designed the study and analysed the data. ZL and HLL drafted the manuscript. HLL, MFT and BMYC made review comments. All authors critically revised the manuscript and had responsibility for the final content.

Corresponding author

Correspondence to Bernard Man Yung Cheung.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval

NHANES protocol was approved by the NCHS Research Ethics Review Board and all participants gave informed consent prior to conducting NHANES.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lin, Z., Li, H.L., Tsoi, M.F. et al. Hypokalaemia associated with hydrochlorothiazide used in the treatment of hypertension in NHANES 1999–2018. J Hum Hypertens (2022). https://doi.org/10.1038/s41371-022-00704-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41371-022-00704-x

Search

Quick links